Russian Heart Failure Journal 2007year Options of drug therapy for the diastolic form of chronic heart failure
Options of drug therapy for the diastolic form of chronic heart failure
Skibitsky V.V., Fendrikova A.V., Kudryashov E.A.
Urgency. Epidemiological studies evidence that up to 85% of patients have CHF due to LV diastolic dysfunction. Aim: Evaluating the effect of different pharmacotherapeutic options on parameters of LV diastolic dysfunction. Materials and methods. Study enrolled 104 patients with the diastolic form of CHF. Patients were randomized to 3 groups; group 1 received enalapril and losartan; group 2 received enalapril and spironolactone; group 3 received a combination of enalapril, losartan and spironolactone. Clinical state of patients, exercise tolerance and echoCG parameters of LV systolic and diastolic function were evaluated at baseline and after 12 months of treatment. Results. All treatment options significantly improved the clinical state of patients and echoCG parameters. However the three-component therapy exerted the most pronounced effect on parameters of LV diastolic function. The three-component treatment significantly increased the number of patients without diastolic disorders, statistically significantly improved all parameters of LV diastolic function, and significantly improved exercise tolerance as compared to other groups. Therefore the three-component therapy more efficiently influenced clinical and echoCG parameters in patients with diastolic CHF than two-component combinations.